ACTIONS:
A broncholytic agent which acts through selective stimulation of the β2-receptors. It differs from other β2-specific sympathomimetics by the low effective dose, long biological half- life and rapid and complete absorption by oral administration.

Pharmacokinetics:
Invasion half-life of clenbuterol is 1 hr; the distribution corresponds to an open 2-compartment model with a side-compartment. Elimination from plasma takes place in 2 phases, the half-life of the α-phase being 1 hr and that of the α-phase 34 hrs. Elimination is primarily renal (87% after 168 hrs). Dose intervals of 12 hrs suffice to maintain a plasma level. 5 metabolites have been found in humans.

INDICATIONS:
Prophylaxis and therapy of bronchospasm in bronchial asthma, chronic bronchitis and bronchitis associated with emphysema.

DOSAGE & ADMINISTRATION:
The recommended total daily dose for adults and children >12 years is 0.04 mg/day In severe bronchospasm the dose may be increased to 0.08 mg/day twice daily; as therapy continues, the dose may often be reduced to 0.02 mg/day.
Tablet: Adults and Children > 12 years: 0.02 mg twice daily. Children < 12 years: According to body weight.

OVERDOSAGE:
Overdosage may cause restlessness, anxiety, flushing, tachycardia, pronounced tremor or rise in blood pressure. With tremor, enzymes specific to muscle cells increase in the serum. A dose of 0.6 mg CLENBUTEROL® was tolerated without complications after a α-blocker was given approximately 90 min after administration.

Treatment:
Symptoms disappear immediately upon administration of a α-blocker. Treatment of overdosage should be cumulative at short interval, depending upon the clinical picture. It should be noted that the action of clenbuterol can extend beyond that of the antagonist, so that it may be necessary to repeat the administration of the α-blocker.
CONTRAINDICATIONS:
Thyrotoxicosis, idiopathic hypertrophic subvalvular aortic stenosis, tachycardia, tachyarrhythmia.

CONTRAINDICATIONS:
Thyrotoxicosis, idiopathic hypertrophic subvalvular aortic stenosis, tachycardia, tachyarrhythmia.

PRECAUTIONS:
Caution should be used when treating patients with recent cardiac infarction.

Use in pregnancy:
Although animal experiments showed no teratogenic effects, CLENBUTEROL® should not be used during the 1st trimester of pregnancy. Because of its labour-inhibiting action, it should not be taken shortly before childbirth.

SIDE EFFECTS:
As with all β-mimetics, CLENBUTEROL® may produce tremor especially at the beginning of treatment. Occasionally, restlessness, extrasystoles and tachycardia may occur at therapeutic doses.

INTERACTIONS:
Beta-blockers and CLENBUTEROL® counteract the action of each other.

How Supplied :
Clenbuterol 0.02 mg issupplied in bottle of 200 white tablets
Do not store above 30°C or 86°F

Manufactured by: LA Pharma S.r.l. Italy